Anti-ETN antibody status.
| Patients Testing Positive for Anti-ETN Antibodies | ||||
|---|---|---|---|---|
| eoJIA, n/N (%) | ERA, n/N (%) | PsA, n/N (%) | Overall, n/N (%) | |
| Week 12 | 0/56 | 4/36 (11.1) | 2/28 (7.1) | 6/120 (5.0) |
| Week 48 | 7/55 (12.7) | 4/34 (11.8) | 3/27 (11.1) | 14/116 (12.1) |
| Week 96 | 7/52 (13.5) | 3/29 (10.3) | 4/24 (16.7) | 14/105 (13.3) |
| Overall | 11/60 (18.3) | 9/38 (23.7) | 6/29 (20.7) | 26/127 (20.5) |
eoJIA: extended oligoarthritis (in juvenile idiopathic arthritis); ERA: enthesitis-related arthritis; ETN: etanercept; PsA: psoriatic arthritis.